Structure Therapeutics (NASDAQ:GPCR) Upgraded to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Structure Therapeutics (NASDAQ:GPCR) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

A number of other brokerages have also recently commented on GPCR. Guggenheim raised their price target on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright raised their target price on shares of Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a report on Friday, December 19th. BMO Capital Markets restated an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, January 6th. Zacks Research lowered shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.45.

Structure Therapeutics Trading Down 2.0%

NASDAQ GPCR opened at $91.87 on Tuesday. The company has a market cap of $5.57 billion, a price-to-earnings ratio of -75.30 and a beta of -2.05. The company has a 50 day moving average of $59.82 and a 200-day moving average of $36.02. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). On average, equities research analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. boosted its position in Structure Therapeutics by 101.9% during the 2nd quarter. Osaic Holdings Inc. now owns 63,362 shares of the company’s stock worth $1,314,000 after buying an additional 31,972 shares during the period. Birchview Capital LP bought a new position in shares of Structure Therapeutics during the second quarter valued at $747,000. Envestnet Asset Management Inc. acquired a new position in shares of Structure Therapeutics during the second quarter worth $221,000. Allianz Asset Management GmbH bought a new stake in shares of Structure Therapeutics in the second quarter worth $228,000. Finally, Bellevue Group AG increased its holdings in Structure Therapeutics by 57.2% in the second quarter. Bellevue Group AG now owns 348,527 shares of the company’s stock valued at $7,228,000 after purchasing an additional 126,812 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.